A study to evaluate efficacy and safety of Vedolizumab in pediatric subjects with moderately to severely active Ulcerative Colitis
- Conditions
- Moderately to severely active Ulcerative Colitis (UC)MedDRA version: 20.1Level: LLTClassification code 10066678Term: Acute ulcerative colitisSystem Organ Class: 100000004856Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
- Registration Number
- EUCTR2020-004300-34-GR
- Lead Sponsor
- Takeda Development Center Americas, Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- 120
1. The subjects aged 2 to 17 years, inclusive, at the time of screening
and enrollment into the maintenance phase of the study.
2. The subject weighs =10 kg at the time of screening and enrollment
into the study.
3. Subjects with moderately to severely active UC diagnosed at least 1 of Mayo endoscopic subscore, stool frequency subscore, and rectal
bleeding subscore) with a Mayo endoscopic subscore of =2 (with the
presence of mucosal friability excluding an endoscopic subscore of 1 and
mandating a score of at least 2).
4. Subjects who have failed, lost response to, or been intolerant to
treatment with at least 1 of the following agents: corticosteroids,
immunomodulators (eg, azathioprine, 6-mercaptopurine, methotrexate),
and/or TNF-a antagonist therapy (eg, infliximab, adalimumab). This
includes subjects who are dependent on corticosteroids to control
symptoms and who are experiencing worsening of disease when
attempting to wean off corticosteroids.
5. Subjects with evidence of UC extending proximal to the rectum (ie,
not limited to proctitis), at a minimum.
6. Subjects with extensive colitis or pancolitis of >8 years' duration or
left-sided colitis of >12 years' duration must have documented evidence
of a negative surveillance colonoscopy within 12 months before
screening.
7. Subjects with vaccinations that are up to date based on the
countrywide, accepted schedule of childhood vaccines.
Are the trial subjects under 18? yes
Number of subjects for this age range: 120
F.1.2 Adults (18-64 years) no
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
1. Subjects who have had previous exposure to approved or investigational anti-integrins including, but not limited to natalizumab, efalizumab, etrolizumab, or AMG 181, or mucosal addressin cell adhesion molecule-1 antagonists or rituximab.
2. Subjects who have had prior exposure to vedolizumab.
3. Subjects with hypersensitivity or allergies to any of the vedolizumab excipients.
4. Subjects who have received either (1) an investigational biologic (other than those listed in Exclusion Criterion #1) within 60 days or 5 half-lives before screening (whichever is longer); or (2) an approved biologic or biosimilar agent within 2 weeks before the first dose of study drug or at any time during the screening period.
5. Subjects with active cerebral/meningeal disease, signs/symptoms or history of progressive multifocal leukoencephalopathy (PML) or any other major neurological disorders including stroke, multiple sclerosis, brain tumor or neurodegenerative disease.
6. Subjects who currently require surgical intervention or are anticipated
to require surgical intervention for UC during this study.
7. Subjects who have had subtotal or total colectomy or have a jejunostomy, ileostomy, colostomy, ileo-anal pouch, or known fixed stenosis of the intestine.
8. Subjects with a current diagnosis of indeterminate colitis.
9. Subjects with clinical features suggesting monogenic very early onset inflammatory bowel disease.
10. The subject has other serious comorbidities that will limit his or her ability to complete the study
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method